Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry

Am J Transplant. 2015 May;15(5):1267-82. doi: 10.1111/ajt.13171. Epub 2015 Feb 19.


This study was a retrospective analysis of the European Liver Transplant Registry (ELTR) performed to compare long-term outcomes with prolonged-release tacrolimus versus tacrolimus BD in liver transplantation (January 2008-December 2012). Clinical efficacy measures included univariate and multivariate analyses of risk factors influencing graft and patient survival at 3 years posttransplant. Efficacy measures were repeated using propensity score-matching for baseline demographics. Patients with <1 month of follow-up were excluded from the analyses. In total, 4367 patients (prolonged-release tacrolimus: n = 528; BD: n = 3839) from 21 European centers were included. Tacrolimus BD treatment was significantly associated with inferior graft (risk ratio: 1.81; p = 0.001) and patient survival (risk ratio: 1.72; p = 0.004) in multivariate analyses. Similar analyses performed on the propensity score-matched patients confirmed the significant survival advantages observed in the prolonged-release tacrolimus- versus tacrolimus BD-treated group. This large retrospective analysis from the ELTR identified significant improvements in long-term graft and patient survival in patients treated with prolonged-release tacrolimus versus tacrolimus BD in primary liver transplant recipients over 3 years of treatment. However, as with any retrospective registry evaluation, there are a number of limitations that should be considered when interpreting these data.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Europe
  • Female
  • Graft Rejection
  • Graft Survival
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy
  • Kaplan-Meier Estimate
  • Liver Failure / mortality
  • Liver Failure / surgery*
  • Liver Transplantation / methods*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Registries
  • Retrospective Studies
  • Risk Factors
  • Tacrolimus / administration & dosage*
  • Treatment Outcome


  • Immunosuppressive Agents
  • Tacrolimus